Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Soclenicant

From Wikipedia, the free encyclopedia
(Redirected fromBNC-210)
Chemical compound
Pharmaceutical compound
Soclenicant
Clinical data
Other namesBNC210; BNC-210; IW2143; IW-2143;L-Isoleucyl-L-tryptophan
Routes of
administration
Oral
Drug classα7-Nicotinic acetylcholine receptornegative allosteric modulator
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Bioavailability69.4% (rat)[1][2]
Protein binding70–88%[1][2]
Eliminationhalf-life6.2 hours (rat)[1][2]
Identifiers
  • L-isoleucyl-L-tryptophan
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC17H23N3O3
Molar mass317.389 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N
  • InChI=1S/C17H23N3O3/c1-3-10(2)15(18)16(21)20-14(17(22)23)8-11-9-19-13-7-5-4-6-12(11)13/h4-7,9-10,14-15,19H,3,8,18H2,1-2H3,(H,20,21)(H,22,23)/t10-,14-,15-/m0/s1
  • Key:BVRPESWOSNFUCJ-LKTVYLICSA-N

Soclenicant (INNTooltip International Nonproprietary Name),[3] also known by its developmental code namesBNC210 andIW-2143 and asL-isoleucyl-L-tryptophan, is anantinicotinic agent which is under development for the treatment ofanxiety disorders such associal phobia andgeneralized anxiety disorder, as well as for treatment ofagitation,post-traumatic stress disorder (PTSD), anddepressive disorders.[1][4][5] It is takenby mouth.[4]

The drug acts as a highlyselectivenegative allosteric modulator (NAM) of theα7-nicotinic acetylcholine receptor7-nAChR).[1][6][4][5] It producesanxiolytic-,anti-stress-, andantidepressant-like effects without causingsedation,memory ormotor impairment, orphysical dependence in rodents.[6] Chemically, soclenicant is adipeptide of theamino acidsL-tryptophan andL-isoleucine and can be considered atryptaminederivative.[7]

Soclenicant is being developed by Bionomics.[4] It has also been developed by Ironwood Pharmaceuticals and EmpathBio.[4][5] Bionomics was acquired by Neuphoria Therapeutics in December 2024.[4] As of December 2024, soclenicant is inphase 3clinical trials for anxiety disorders,phase 2 trials for agitation and PTSD, and no recent development has been reported for depressive disorders.[4][5] The drug receivedFast Track designation from theUnited StatesFood and Drug Administration (FDA) in 2019.[8] It was first described in the literature, in aconference abstract, by 2007.[2]

See also

[edit]

References

[edit]
  1. ^abcdeHampsey E, Perkins A, Young AH (April 2023). "BNC210: an investigational α7-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders".Expert Opin Investig Drugs.32 (4):277–282.doi:10.1080/13543784.2023.2192922.PMID 36927202.
  2. ^abcdAndriambeloson, E., Wagner, S., Huyard, B., Sleebs, B., Quasi, N., Bui, C., ... & Street, I. (2007, September). BNC210: A Novel Compound with Potent Anxiolytic Activity. In Behavioral Pharmacology (Vol. 18, pp. S16–S16).https://neurofit.com/im-posters/2008-ebps-bnc210.pdf
  3. ^https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf#page=198 soclenicantum soclenicant 6-[(2,3-dihydro-1H-inden-2-yl)amino]-1-ethyl-3-(morpholine4-carbonyl)-1,8-naphthyridin-4(1H)-one nicotinic acetylcholine receptor negative allosteric modulator, anxiolytic
  4. ^abcdefg"BNC 210".AdisInsight. 30 December 2024. Retrieved22 February 2025.
  5. ^abcd"Delving into the Latest Updates on BNC-210 with Synapse".Synapse. 23 January 2025. Retrieved22 February 2025.
  6. ^abO'Connor SM, Sleebs BE, Street IP, Flynn BL, Baell JB, Coles C, Quazi N, Paul D, Poiraud E, Huyard B, Wagner S, Andriambeloson E, de Souza EB (March 2024)."BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, demonstrates anxiolytic- and antidepressant-like effects in rodents".Neuropharmacology.246: 109836.doi:10.1016/j.neuropharm.2024.109836.PMID 38185416.
  7. ^"CID 7019084".PubChem. Retrieved22 February 2025.
  8. ^Bionomics Limited Press Release (2019-11-04)."Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD". BusinessWire. Retrieved2020-09-09.
nAChRsTooltip Nicotinic acetylcholine receptors
Agonists
(andPAMsTooltip positive allosteric modulators)
Antagonists
(andNAMsTooltip negative allosteric modulators)
Precursors
(andprodrugs)
Tryptamines
N-Acetyltryptamines
α-Alkyltryptamines
Triptans
Cyclized tryptamines
Isotryptamines
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=Soclenicant&oldid=1277390061"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp